AlphAIAlphAI — Financial news for AI agents
ctvnews.caNOV 32 min read$PFE

Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat

Pfizer raised its 2026 forecasts after strong Q3 results, driven by cancer drugs and Eliquis. Revenue was $16.58B, beating estimates. The company targets $62B-$64B in annual sales, up from prior forecasts. Adjusted EPS is expected to be $2.95-$3.05. Pfizer aims for $9.7B in cost savings by 2029. CEO Albert Bourla cited strong performance and confidence in growth prospects.

Original reporting
ctvnews.ca
Published Nov 3, 2026, 1:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PFE
Bullish
high confidence
Mentioned
$PFE
Relevance
9/10
AlphAI data visualization · based on ctvnews.ca
Decision brief

The 30-second read

$PFEBullishHigh
01

Why it matters

The raised guidance is a primary catalyst for price movement, reflecting strong demand for Eliquis and cancer drugs.

02

Market read

Guidance lift is material for investors and may drive short‑term price appreciation.

03

What to watch

Potential regulatory scrutiny of new licensing deals could temper upside.

Relevance 9/10Novelty 9/10Timing: after-hours today

Background

Pfizer reported Q3 results beating estimates and announced an upgraded full‑year outlook.

Company-level read

Ticker impact

$PFEBullishHigh confidence
Context

Pfizer raised its 2026 sales forecast to $62‑64 B and EPS outlook to $2.95‑$3.05, beating prior guidance.

Expected impact

likely upward as investors price in higher sales and earnings expectations

Evidence & confidence

The new forecast exceeds consensus and reflects strong drug demand, which should support the stock price.

Market effects

Sector

Higher pharma earnings outlook may lift biotech and specialty drug peers.

Regional

U.S. market may see modest gains in healthcare indices.

Global

Improved outlook could boost global pharma sentiment, especially in markets tracking U.S. earnings.

Counterpoint

What could challenge this read

If cost cuts fall short or COVID product revenue declines faster, the guidance may be overly optimistic.

Key entities

  • company
    Pfizer

    U.S. pharmaceutical giant issuing the new guidance.

Read at source← All news

StoryPfizer posts Q3 beat, raises FY‑26 outlook and names new CFO

Also covered by

3 outlets

Related articles

NOV 3
$PFEHighAI 9/10

Pfizer Q3 2026 earnings beat estimates, full-year outlook raised

Pfizer reported Q3 2026 revenue of $16.58B, down slightly YoY but up 7% excluding Comirnaty and Paxlovid. Full-year revenue guidance raised to $62B-$64B, with adjusted EPS of $2.95-$3.05. The outlook includes a $650M charge from an agreement with Innovent Biologics. Analysts expected lower revenue and EPS.

qz.com2 min
NOV 3
$PFEHighAI 9/10

Pfizer raises sales forecast after Q3 2026 earnings beat

Pfizer raised its 2023 revenue forecast to $62.0B-$64.0B, up from $60.5B-$62.5B, and adjusted EPS guidance to $2.95-$3.05. Q3 revenue was $16.6B, flat YoY, with adjusted EPS at 87 cents. Revenue from launched and acquired products rose 32%, while Paxlovid and Comirnaty revenue declined.

qz.com2 min